Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edith M G van Esch

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Nature Communications|June 10, 2015
The interferon-related developmental regulator 1 is used by human papillomavirus to suppress NFκB activationBart Tummers, Renske Goedemans, Laetitia P L Pelascini, et al.
International Journal of Cancer|September 16, 2014
Expression of coinhibitory receptors on T cells in the microenvironment of usual vulvar intraepithelial neoplasia is related to proinflammatory effector T cells and an increased recurrence-free survivalEdith M G van Esch, Mariette I E van Poelgeest, Simone Kouwenberg, et al.
Journal for Immunotherapy of Cancer|March 15, 2020
Pre-existing inflammatory immune microenvironment predicts the clinical response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 vaccinationZiena Abdulrahman, Noel de Miranda, Edith M G van Esch, et al.
International Journal of Cancer|June 24, 2020
A pre-existing coordinated inflammatory microenvironment is associated with complete response of vulvar high-grade squamous intraepithelial lesions to different forms of immunotherapyZiena Abdulrahman, Noel F C C de Miranda, Bart W J Hellebrekers, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 22, 2013
Clinical characteristics associated with development of recurrence and progression in usual-type vulvar intraepithelial neoplasiaEdith M G van Esch, Maija C I Dam, Michelle E M Osse, et al.
Journal for Immunotherapy of Cancer|October 21, 2025
Pre-existing infiltration with T cells and CD14+ myeloid cells is associated with treatment response to imiquimod in primary and recurrent vulvar high-grade squamous intraepithelial lesionsCaroline L P Muntinga, Peggy J de Vos van Steenwijk, Loes F S Kooreman, et al.
Journal of Gynecologic Oncology|January 9, 2026
Risk stratification of groin node metastases in vulvar cancer biopsies based on histology and immunohistochemical stainingGuus Veldmate, Renée M F Ebisch, Noortje Pleunis, et al.
Acta Obstetricia Et Gynecologica Scandinavica|July 9, 2025
Improving imiquimod use in cervical high-grade squamous intraepithelial lesions: A qualitative studyCaroline L P Muntinga, Helena C J Schellekens, Charlotte G J Penders, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|March 31, 2024
Topical imiquimod treatment of residual or recurrent cervical intraepithelial neoplasia lesions (TOPIC-2): A randomised controlled trialAnna J M van de Sande, Romy van Baars, Margot M Koeneman, et al.
Cancers|June 13, 2025
Risk Factors for Wound Complications in Vulvar Cancer Surgery and Indications for Reconstructive SurgeryJustin J E Delahaije, Ephrahim E Jerry, Saskia Houterman, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Nature Communications|June 10, 2015
The interferon-related developmental regulator 1 is used by human papillomavirus to suppress NFκB activationBart Tummers, Renske Goedemans, Laetitia P L Pelascini, et al.
International Journal of Cancer|September 16, 2014
Expression of coinhibitory receptors on T cells in the microenvironment of usual vulvar intraepithelial neoplasia is related to proinflammatory effector T cells and an increased recurrence-free survivalEdith M G van Esch, Mariette I E van Poelgeest, Simone Kouwenberg, et al.
Journal for Immunotherapy of Cancer|March 15, 2020
Pre-existing inflammatory immune microenvironment predicts the clinical response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 vaccinationZiena Abdulrahman, Noel de Miranda, Edith M G van Esch, et al.
International Journal of Cancer|June 24, 2020
A pre-existing coordinated inflammatory microenvironment is associated with complete response of vulvar high-grade squamous intraepithelial lesions to different forms of immunotherapyZiena Abdulrahman, Noel F C C de Miranda, Bart W J Hellebrekers, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 22, 2013
Clinical characteristics associated with development of recurrence and progression in usual-type vulvar intraepithelial neoplasiaEdith M G van Esch, Maija C I Dam, Michelle E M Osse, et al.
Journal for Immunotherapy of Cancer|October 21, 2025
Pre-existing infiltration with T cells and CD14+ myeloid cells is associated with treatment response to imiquimod in primary and recurrent vulvar high-grade squamous intraepithelial lesionsCaroline L P Muntinga, Peggy J de Vos van Steenwijk, Loes F S Kooreman, et al.
Journal of Gynecologic Oncology|January 9, 2026
Risk stratification of groin node metastases in vulvar cancer biopsies based on histology and immunohistochemical stainingGuus Veldmate, Renée M F Ebisch, Noortje Pleunis, et al.
Acta Obstetricia Et Gynecologica Scandinavica|July 9, 2025
Improving imiquimod use in cervical high-grade squamous intraepithelial lesions: A qualitative studyCaroline L P Muntinga, Helena C J Schellekens, Charlotte G J Penders, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|March 31, 2024
Topical imiquimod treatment of residual or recurrent cervical intraepithelial neoplasia lesions (TOPIC-2): A randomised controlled trialAnna J M van de Sande, Romy van Baars, Margot M Koeneman, et al.
Cancers|June 13, 2025
Risk Factors for Wound Complications in Vulvar Cancer Surgery and Indications for Reconstructive SurgeryJustin J E Delahaije, Ephrahim E Jerry, Saskia Houterman, et al.
Pageof 3